Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Capital Expenditures (2022 - 2025)

Phathom Pharmaceuticals (PHAT) has disclosed Capital Expenditures for 4 consecutive years, with $178000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Capital Expenditures rose 245.9% to $178000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $229000.0, a 2762.5% increase, with the full-year FY2025 number at $229000.0, up 2762.5% from a year prior.
  • Capital Expenditures was $178000.0 for Q4 2025 at Phathom Pharmaceuticals, up from $42000.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $1.2 million in Q3 2023 to a low of -$491000.0 in Q4 2022.
  • A 4-year average of $125562.5 and a median of $41000.0 in 2024 define the central range for Capital Expenditures.
  • Peak YoY movement for Capital Expenditures: tumbled 125.68% in 2024, then soared 245.9% in 2025.
  • Phathom Pharmaceuticals' Capital Expenditures stood at -$491000.0 in 2022, then skyrocketed by 196.74% to $475000.0 in 2023, then crashed by 125.68% to -$122000.0 in 2024, then skyrocketed by 245.9% to $178000.0 in 2025.
  • Per Business Quant, the three most recent readings for PHAT's Capital Expenditures are $178000.0 (Q4 2025), $42000.0 (Q3 2025), and -$9000.0 (Q2 2025).